Tuesday, March 15, 2011
Gilles Frydman is the head of ACOR, the Association of Cancer Online Resources, founded in 1995 in New York, and the largest online cancer patient community with 65 000 patients and caregivers. ACOR’s 159 electronic lists deliver approximately 1.5 million email messages weekly. The ACOR community has demonstrated its ability to accelerate the distribution of quality information regarding trials, treatments, pharmacovigilance.
Acta Oncologica - summary - Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovaria
Monday, March 14, 2011
Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices -- American Journal of Public Health selected articles
Note: this journal is by subscription ($$$)
AJPH First Look, published online ahead of print Jan 13, 2011
© 2011 American Public Health Association
GOVERNMENT, POLITICS, AND LAW
Sheila M. Rothman is with the Division of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, and the Center for the Study of Society and Medicine,
College of Physicians and Surgeons, Columbia University. Victoria H. Raveis is with the Psychosocial Unit on Health, Ageing, and Community, New York University College of Dentistry, New
York. At the time of the study Anne Friedman was with the Center on Medicine as a Profession, College of Physicians and Surgeons, Columbia University. David J. Rothman is with the College
of Physicians and Surgeons, Columbia University.
Correspondence: Correspondence should be sent to Sheila M. Rothman, Center for the Study of Society and Medicine, College of Physicians and Surgeons, Columbia University,
630 West 168th St, PH 15-25, New York, NY 10032 (e-mail: email@example.com). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" button.
Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's
marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed.
We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns.
Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor.
No HAO disclosed the exact amount of a Lilly grant.
As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators,
and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.
This article has been cited by other articles:
Patient Advocacy Organizations and Corporate Relationships
Am J Public Health, April 1, 2011; 101(4): 582 - 583.
[Full Text] [PDF]
eLetters:Read all eLetters
- Health Advocacy Organizations: Transparency is important and so is evidence
- Frances M Visco
- AJPH Online, 17 Jan 2011 [Full text]
- Patient Advocacy Organizations are Committed to Transparency
- Myrl Weinberg
- AJPH Online, 20 Jan 2011 [Full text]
- Re: Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis
- Jack Harris, et al.
- AJPH Online, 24 Jan 2011 [Full text]
abstract: Patient Advocacy Organizations and Corporate Relationships -- Weinberg 101 (4): 582 -- American Journal of Public Health
April 2011, Vol 101, No. 4 | American Journal of Public Health 582-583
© 2011 American Public Health Association
Myrl Weinberg is president of the National Health Council, Washington, DC.
Correspondence: Correspondence should be sent to Myrl Weinberg, National Health Council, 1730 M Street, NW, Suite 500, Washington, DC 20036-4561 (e-mail: firstname.lastname@example.org). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" link.
The NHC agrees with Rothman et al. about the need for transparency.1 For this reason, any patient advocacy organization that wishes to join or retain its membership in the NHC must disclose funding received from corporations and present the information in an easily accessible manner within 6 months of the close
Note: this refers to the Japanese study published 2010 of weekly Taxol - search blog for the original study and additional commentaries
March 14, 2011 — The updated 2011 National Comprehensive Cancer Network (NCCN) Ovarian Cancer Guidelines have added a new treatment option — dose-dense paclitaxel — for the first-line treatment of stage II, III, or IV epithelial ovarian cancer.
The category 1 recommendation comes from data from the Japanese Gynecologic Oncology Group, said panel chair Robert J. Morgan, MD, professor of medicine at the City of Hope Comprehensive Cancer Center in Duarte, California, here at the NCCN 16th Annual Conference.
In a phase 3 open-label randomized controlled trial published in the Lancet (2009; 374:1331-1338), Noriyuki Katsumata and colleagues reported that dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer resulted in a significant survival advantage. The study concluded that paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.
"This was an important addition," Dr. Morgan told Medscape Medical News........"
PharmaLive: Topotarget Announces Updates on Belinostat in Two Clinical Trials - NSCLC and Ovarian Cancer (negative study ovarian/Belinostat/Carboplatin)
Ovarian cancer – GOG 0126-T (NCI-driven study)
Preliminary analysis of GOG 0126-T trial has not shown enough activity to enter into second stage. Consequently the study will be ended.
The study is an open-label single-arm phase II trial with belinostat in combination with carboplatin given to patients with ovarian cancer who progress during or shortly after first-line treatment with platinum containing chemotherapy. The trial is sponsored by the GOG with support from the NCI. Belinostat is administered as a 30-minute daily IV infusion on day one through five with carboplatin being administered on day three. Treatment is given every third week and is repeated until disease progression......
Gastroenterology & Endoscopy News - Gastros Outperform Oncologists in Recognition of Inherited CRC (Lynch Syndrome/PJS/FAP....extracolonic tumors)
Note: access is free/requires registration
"......Overall, physicians benefited from the educational intervention, scoring significantly higher on exams about genetic testing for Lynch syndrome, FAP and Peutz-Jeghers syndrome post-test than at baseline. The education session also significantly improved physicians’ recognition of Lynch syndrome family pedigrees and surveillance of the disease, but did not effectively enhance awareness of extra-colonic manifestations.
Although the educational intervention improved the ability of physicians to identify families with multiple members affected by CRC, it did not help them spot extra-colonic cancers in families with Lynch syndrome. Identifying extra-colonic cancers is important because Lynch syndrome increases a person’s risk for endometrial cancer and is associated with cancers of the stomach (6%-9%); ovaries (6%-12%); and ureter and renal pelvis (3%-8%) (and others), according to the Colon Cancer Alliance for Research and Education for Lynch Syndrome...........cont'd
"Ms. (Kate) Murphy has survived ovarian and breast cancer as well as three episodes of colon cancer."
abstract: Revised Bethesda Guidelines: compliance in identifying HNPCC affected families (Lynch Syndrome)
Based on these results, there is a marked incompliance with revised Bethesda guidelines when assessing patients with colorectal cancer. This has a significant impact on clinical pathways for the management of HNPCC (Lynch Syndrome) families.
Sunday, March 13, 2011
Hover over each satellite photo to view the devastation caused by the earthquake and tsunami.
"In summary, fertility-preserving attempts have succeeded in patients with ovarian or testicular cancer and in males with Hodgkin lymphoma."
abstract: Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors (endometrioid/clear cell cell types) MSH2 MSH6 MLH1
Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
AbstractOBJECTIVE: Heredity is a major cause of ovarian cancer and during recent years the contribution from germline mismatch repair (MMR) gene mutations linked to Lynch syndrome has gradually been recognized.
METHODS: We characterized clinical features, tumor morphology and mismatch repair defects in all ovarian cancers identified in Swedish and Danish Lynch syndrome families.
RESULTS: In total, 63 epithelial ovarian cancers developed at mean 48 (range 30-79) years of age with 47% being early stage (FIGO stage I). Histologically, endometrioid (35%) and clear cell (17%) tumors were overrepresented. The underlying MMR gene mutations in these families affected MSH2 in 49%, MSH6 in 33% and MLH1 in 17%. Immunohistochemical loss of the corresponding MMR protein was demonstrated in 33/36 (92%) tumors analyzed.
CONCLUSION: The combined data from our cohorts demonstrate that ovarian cancer associated with Lynch syndrome typically presents at young age as early-stage, non-serous tumors, which implicates that a family history of colorectal and endometrial cancer should be specifically considered in such cases.
abstract: BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer (Slovenia)
abstract: Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer
Saturday, March 12, 2011
- complete penetrance. The allele is said to have complete penetrance if all individuals who have the disease-causing mutation have clinical symptoms of the disease.
- highly penetrant. If an allele is highly penetrant, then the trait it produces will almost always be apparent in an individual carrying the allele.
- incomplete penetrance or reduced penetrance. Penetrance is said to be reduced or incomplete when some individuals fail to express the trait, even though they carry the allele.
- low penetrance. An allele with low penetrance will only sometimes produce the symptom or trait with which it has been associated at a detectable level. In cases of low penetrance, it is difficult to distinguish environmental from genetic factors.
Thursday, March 10, 2011
"Lynch syndrome, previously referred to as hereditary non-polyposis colorectal cancer or HNPCC, represents the most common hereditary cause of colorectal cancer.
Approximately 1 in 400 to 1 in 500 individuals in the general population are estimated to have Lynch syndrome.
Knowledge, as they say, in this condition, is power. Not only should individuals with Lynch syndrome start their colonoscopies earlier (at 20-25 years of age) and have them more frequently (every 1-2 years), they should also be screened for stomach and small intestine cancer, urinary tract cancers involving the kidneys and ureters, and the hepatobiliary tract, including the gallbladder, bile duct, pancreas and liver.
Further, women with Lynch syndrome should be aware of the increased risk for both endometrial and ovarian cancer and offered the option of prophylactic surgery following childbearing."
March 2011: Hereditary Cancer in Clinical Practice | Full text | Lynch Syndrome - is breast cancer a feature?
The debate on whether or not breast cancer is in the tumor spectrum for Lynch syndrome produces a conundrum for healthcare providers.
The classic tumor spectrum for Lynch Syndrome (LS) includes colon, endometrial, ovarian, stomach, small intestine, hepatobiliary, urinary tract and brain/central nervous system cancers. Muir-Torre Syndrome (MTS) is a variant of LS that is associated with additional skin lesions including sebaceous gland tumors and keratoacanthomas. MTS was observed in 28% of LS families when assessing for MTS skin lesions . It has also been reported that 10-14% of individuals with MTS present initially with breast cancer [2,3]. An extensive study published in 2002 excluded breast cancer as part of the tumor spectrum associated with LS .
However, more recently it was reported that DNA mismatch repair (MMR) gene deficiencies were identified in 51% of breast cancers arising in MMR mutation carriers . Another study reported a male with an MLH1 mutation who had both colon and breast cancer. The breast cancer exhibited somatic reduction to homozygosity for the MLH1 mutation .
Here we report two unrelated families in which the proband has a germline MMR gene mutation and bilateral breast cancer, and one family in which the proband had ovarian and renal cancer and her daughter, maternal aunt and cousin had breast cancer at age 47, 59, and 48 respectively.
This raises the question are these breast cancers associated with the MMR mutations or a breast cancer susceptibility gene and what testing should be offered?
ConclusionOur findings indicate that breast cancer is part of the spectrum of tumors in LS families in which the breast cancer segregates with the other LS associated tumors.
Additional hereditary breast cancer gene testing may not be warranted in these circumstances. A future research goal is to perform IHC on the breast tumors from these families to determine if they show loss of expression of the MMR gene that is known to be altered.
....cont'd (full free access)
Note: forwarded from patient safety community, sad situation/s really
Number of U.S. Cancer Survivors Grows to Nearly 12 Million
The number of cancer survivors in the United States increased from 3 million in 1971 to 11.7 million in 2007, according to a new study by CDC and the National Cancer Institute.
A cancer survivor is defined as anyone who has been diagnosed with cancer, from the time of diagnosis through the balance of his or her life. Cancer survivors largely consist of people who are 65 years of age or older and women. Many people with cancer live a long time after diagnosis; more than a million people were alive in 2007 after being diagnosed with cancer 25 years or more earlier.
Of the 11.7 million people living with cancer in 2007—
- 7 million were 65 years of age or older.
- 6.3 million were women.
- 4.7 million were diagnosed 10 years earlier or more.
Cancer survivors—United States, 2007. MMWR 2011;60(9):269–272.
TABLE. Estimated number of living persons ever diagnosed with cancer, by age group and cancer type --- United States, January 1, 2007
Age group (yrs)
Wednesday, March 09, 2011
Linus Pauling Institute at Oregon State University (research institute vitamins/micronutriends/phytochemicals)
NIH/NCCAMThe Linus Pauling Institute is one of the nation's first two Centers of Excellence for Research on Complementary and Alternative Medicine designated by the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH).
Center of Excellence
Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....
Dr Bradley Monk interviews 6 nationally recognized experts in GYN oncology about their interpretations of clinically relevant data presented at the annual meeting. Drs Deborah Armstrong, Barbara Goff, Tom Herzog, Warner Huh, Robert Coleman, and Robert Burger comprise the esteemed faculty.
Dr Henry Lynch, Sr (Lynch Syndrome) - Omaha doctor pioneered genetic cancer concept - LivewellNebraska.com
Articles in Press
|Volume 120 (2011)|
|Volume 120, Issue 3 - selected|
pp. 317-492 (March 2011)
Technologic Innovations and Novel Surgical Approaches for Patients with Gynecologic Malignancies
|Volume 120, Issue 2|
pp. 165-316 (February 2011)
|Volume 120, Issue 1|
pp. 1-164 (January 2011)
|Volume 120, Supplement 1|
pp. S1-S150 (March 2011)
ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS, ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS
Journal Gynecologic Oncology, Volume 120, Supplement 1, Pages S1-S150 (March 2011) abstracts to be presented at 2011 annual SGO meeting
Note: this journal is by subscription ($$$) for full access, the actual abstracts via this indexed list are not available - titles of presentations only - abstracts either have been previously published or to come
Volume 120, Supplement 1, Pages S1-S150 (March 2011)
ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS
Orlando, FL USA
Ovarian cancer: early detection saves lives | McGill University (Montreal) Health Centre - the Dove Project
For more information about DOVE: http://muhc.ca/royalvic/article/dove-project
financial news: Healthcare Stock on Watch; Vermillion (OVA1) climbs on Poster Presentation | Beacon Equity: Penny Stocks, Stock Alerts
Healthcare Stock on Watch; Vermillion climbs on Poster Presentation
The poster evaluated more than 20 candidate biomarkers for their ability to complement the company’s CA125 in distinguishing benign ovarian tumors from malignant ones.
Medical News: Bevacizumab Value in Ovarian Cancer Questioned - in Clinical Context, Ovarian Cancer from MedPage Today
Note: the actual study including those related to Avastin/breast cancer were previously posted (on this blog) but this particular Medscape article may be easier to read.
Search blog (top left hand column or sidebar) via key word Avastin.
NCI Cancer Bulletin Mar 2011: Ovarian Cancer Study Raises Questions about Developing Markers for Early Detection
"A long-awaited assessment of potential biomarkers for detecting early ovarian cancer shows that blood levels of the CA-125 protein remain the best predictor of the disease. But if there is to be any hope that screening will reduce deaths from this disease, then more accurate markers would have to be developed, researchers concluded in the March Cancer Prevention Research. (note: also see blog postings for related abstracts)
None of the 28 potential serum markers tested in the study outperformed CA-125. But for screening, the researchers noted, doctors would need a test that could detect a signal from tumors more than 6 months before diagnosis; CA-125 had its strongest signal within 6 months of diagnosis.
Although the results may seem disappointing, the findings can inform future efforts to detect the disease early, the study authors wrote. This idea was echoed by several biomarker experts who were not involved in the work but who stressed the importance of the findings......."cont'd
2011 March Cancer Prevention Research articles/references: Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens — Cancer Prev Res
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens
- Ian Jacobs and
- Usha Menon
- Perspectives: Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer Detection
- Phuong L. Mai,
- Nicolas Wentzensen,
- and Mark H. Greene
Articles citing this article
- The Sine Qua Non of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples Cancer Prev Res March 1, 2011 4:299-302
- A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer Cancer Prev Res March 1, 2011 4:375-383
- Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer Detection Cancer Prev Res March 1, 2011 4:303-306
Tuesday, March 08, 2011
Mabcure Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the SGO - financial news
"Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here..........."
worth reading - Medical News: SGO: PARP Inhibitor Active in Ovarian Cancer - in Meeting Coverage, SGO from MedPage Today
......"Antitumor activity was observed in heavily pretreated BRCA1 and BRCA2 mutation carriers, and preliminary antitumor activity was seen in patients with sporadic cancers," said Robert Wenham, MD, of the H. Lee Moffitt Cancer Center in Tampa, Fla...........During the initial dose-escalation phase, the patient population was enriched with BRCA1/2 mutation carriers. In the dose-expansion phase of the trial, investigators enrolled patients with sporadic platinum-resistant high-grade serous ovarian cancer......cont'd
Drug naming standard for electronic health records enhanced, March 8, 2011 News Release - National Institutes of Health (NIH)
Cancer Clinical Trial: Existential Issues in Elderly People With Cancer [Conditions: Cancer] (aged people with cancer)
Detailed Clinical Trial Description
Arms, Groups and Cohorts in this Clinical Trial: Cancer in elderly people
Planned Data Points Publications:Utilization of erythropoietin-stimulating agents
Utilization of anti-cancer biologic products
Utilization of anti-cancer biologic products by diagnosis
Medicare reimbursements by recurrent ICD-9 categories
abstract: Health-related quality of life and cancer clinical trials (University of British Columbia)
Note: consider values? whose?
".....The overall outlook for the routine assessment of patient-reported outcomes in clinical trials is assured and, eventually, it is likely to become a standard part of clinical practice. However, there is still a need for a clear method for determining the clinical meaningfulness of changes in scores. The answer will probably come from the greater use of patient-reported outcomes and the consequent growth of experience that is necessary to make such judgements."
Review - EvidenceUpdates: Congestive heart failure risk in patients with breast cancer treated with bevacizumab/Avastin (including professional commentary)
1) link including professional commentary (BMJ Evidence Centre/McMaster)
2) additional link to abstract (JCO)
March 2011 Hormone therapy still has a place for treating menopause symptoms - Harvard Health Publications
Note: WHI (Women's Health Initiative)
"....But the WHI left many questions unanswered.....cont'd
Monday, March 07, 2011
(references SGO presentation) PCPs less likely to refer patients to gynecologic oncologists | HemOncToday
"..........Just 39.3% of family physicians and 51% of internists reported that they would refer the patient to the gynecologic oncologist. They were much more likely to refer their patients to obstetrician-gynecologists. Among obstetrician-gynecologists, however, two-thirds reported that they would refer a patient with abdominal pain and a suspicious ovarian mass to a gynecologic oncologist.........One-third of the obstetrician-gynecologists reported that they would operate on the patient themselves.........."
Goff B. #10. Presented at: the 42nd Annual Meeting of the Society of Gynecologic Oncologists; March 6-9, 2011, Orlando, Fla.
Note: see press release for more details
"OVA1 improves the sensitivity of the ACOG referral guidelines for an ovarian mass"
"OVA1 Has High Sensitivity in Identifying Ovarian Malignancy Compared to Preoperative Assessment and CA125"
- Shirish M. Gadgeel
abstract: JCO - Natural History of (Taxol) Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1
paclitaxel–acute pain syndrome (P-APS) and paclitaxel's
more chronic neuropathy have not been well delineated.
Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) –20
instruments during the entire course of therapy.
Twenty percent of patients had pain scores of 5 to 10 of 10 with
the first dose of paclitaxel. Sensory neuropathy symptoms wer
e more prominent than were motor or autonomic neuropathy
symptoms. Of the sensory neuropathy symptoms, numbness and
tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of
paclitaxel appeared to have more chronic neuropathy.
Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.
swelling, warmth, or redness.
abstract JCO: At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
The addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective. Treatment with maintenance bevacizumab leads to improved PFS but is associated with both direct and indirect costs. The cost effectiveness of bevacizumab in the adjuvant treatment of ovarian cancer is primarily dependent on drug costs.
JCO Editorial + abstract/podcast: Bevacizumab (Avastin) for Advanced Breast Cancer: All Tied Up With a RIBBON? (the Ribbon-1 trial)
- Harold J. Burstein
- [JCO Podcast]
- Breast Cancer RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Note: read the whole article
Ohio State study: Targeted ovarian cancer therapy not cost-effective
COLUMBUS, Ohio – An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.
The findings comparing the relative value of various clinical strategies will be published online March 7 in the Journal of Clinical Oncology (see blog)................ cont'd
"Although a discussion regarding cost-effectiveness of a potentially life-extending intervention invariably suggests the rationing of limited health care resources, the intent of this study was to provide a framework with which to evaluate the pending results of a clinical trial of three different interventions for ovarian cancer, said Cohn."............... cont'd
call for papers: Measuring Consumer Involvement in Health and Social Care: Dividing fact from fiction | Cochrane Consumer Network
Medical News: SGO: Ovarian Ca Patients Shortchanged by Medicare - in Meeting Coverage, SGO from MedPage Today
- Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
- Explain that an analysis of NCI and Medicare databases found that less than 40% of patients over age 65 with advanced ovarian cancer received care that measures up to national standards.
- Note that this study found demographic factors -- including race, marital status, geographic location, and socioeconomic status -- affected whether patients over 65 received optimal treatment.
(Pixantrone ) Cell Therapeutics Inc Announces Meeting with FDA Officials - NASDAQ:CTIC | Galaxy Stocks
(social media) Patient health sites might be delivering bad medicine :: March 1, 2011 ... American Medical News
Sunday, March 06, 2011
still recruiting: Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer - Full Text View - ClinicalTrials.gov
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients - Full Text View - ClinicalTrials.gov
Note Exclusion criteria:
Exclusion Criteria: a. Patients who receive neoadjuvant chemotherapy for their ovarian, primary peritoneal, or fallopian tube cancer are excluded....
"The 10-year analysis of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial1 continues to show a difference in its primary endpoint of disease-free survival, which favours anastrozole as adjuvant treatment for postmenopausal women with hormone-responsive breast cancer. Ultimately, however, clinical trials have two aims: either to show improvement in survival, or in its quality.
Anastrozole has failed to meet these criteria when compared with tamoxifen."
Caris Life Sciences to Present on Biomarker Expression at the Society of Gynecologic Oncologists 2011 Annual Meeting on Women's Cancer
Of or pertaining to a sister; Related through someone's sister
Practically all data on familial risk in ovarian and other cancers are based on incident cancer, whereas familiality in cancer mortality is largely unknown. If fatal forms of cancer are a highly familial subtype, then familial risk for mortality may exceed that of incidence, which is relevant for clinical decision making and counseling.
Ovarian cancer patients in the nationwide Swedish Family Cancer Database were classified according to fatal and nonfatal (incident) family history. Familial risks for incident and fatal ovarian cancer were calculated for offspring based on their parental or sibling family history of any cancer using standardized incidence ratios (SIRs) for incidence and standardized mortality ratios (SMRs) for mortality. Offspring without family history were referents.
The database included 24,757 mothers and 8138 daughters with ovarian cancer. When a mother had ovarian cancer, the SIR for incident ovarian cancer in daughters was 2.69, and when a sister had ovarian cancer it was 3.49. The SMRs for fatal cancer by fatal cancer in probands were 3.39 and 5.80, respectively. For fatal serous cancers among siblings, the SMR was 6.16, compared with 10.01 for the endometrioid type. Ovarian cancer was associated with maternal (SIR, 1.22; SMR, 1.56) and sororal breast cancer (SIR, 1.27). Another discordant association was between ovarian and paternal prostate cancer (SIR, 1.12; SMR, 1.66).
Fatal familial risks were higher for concordant ovarian, ovarian-breast, and ovarian-prostate cancers than the corresponding incident risks. This may suggest that highly fatal subtypes exist for these cancers, calling for genetic dissection. Cancer 2011
Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen- Intl Journal of Cancer
"......Neither current nor former E + P use was associated with ovarian cancer risk (RR 1.08, 95% CI 0.86–1.35; RR 1.08, 95% CI 0.68–1.71, respectively, per 5-year increment). These findings suggest that progestins may mitigate some of the detrimental effects of estrogen on the ovarian epithelium."
Timing of administration of bevacizumab (Avastin) chemotherapy affects wound healing after chest wall port placement - Cancer
Definition: dehiscence - Separation of wound edges.
The authors investigated how the timing of administration of bevacizumab, a targeted vascular endothelial growth factor-inhibiting chemotherapeutic agent, affected the risk of wound healing in patients undergoing chest wall port placement.
The risk of a wound dehiscence requiring chest wall port explant in patients treated with bevacizumab was inversely proportional to the interval between bevacizumab administration and port placement, with significantly higher risk seen when the interval is less than 14 days.
March 2011 (Cancer) The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival
Studies have suggested that erythropoietin-stimulating agents (ESAs) may affect progression-free survival (PFS) and overall survival (OS) in a variety of cancer types. Because this finding had not been explored previously in ovarian or primary peritoneal carcinoma, the authors of this report analyzed their ovarian cancer population to determine whether ESA treatment for chemotherapy-induced anemia affected PFS or OS.
The current results indicated that there was no difference in cancer-related PFS or OS with use of ESA in this cohort of women treated for ovarian cancer.
Saturday, March 05, 2011
Note: see Table 1 for criteria/index of variables
Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma Open Access
Note: see Table 1 for cell types/stage included in study
".......None of the stem cell markers was expressed by all patients’ cells. No correlation with tumor type was demonstrated. The complexity of expression challenges the isolation of cancer stem cell."
abstract (+references) Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer Detection — Cancer Prev Res
Friday, March 04, 2011
Business Line : Companies News : Strides gets EU nod to market ovarian cancer drug (generic Carboplatin)
".......... thus highlighting the need for more extensive sequencing approaches in families where routine procedures fail to find a mutation."
CHSPR - University of British Columbia: 2011 Health Policy Conference BOOMERANGST: Myths and Realities about health care for an aging population (Lewis/Berwick quote...)
1) includes influence of cancer/aging/demographics
2) referenced via Hsien Seow presentation:
"Inbalance. Not by chance.
(Don Berwick quote: every system is perfectly designed to produce exactly the results it gets. A systematic issue.)
We have a system that provide PC only when patients are “dying” or at EOL. – actively dying."
Day 1: February 22, 2011
|8:30 am -- Welcome from the co-chairs|
|Patricia Baird, University of British Columbia||Audio||Slides|
|9:00 am -- Opening Plenary: Myths and Realities about demographics|
|Jay Olshansky, University of Illinois||Audio||Slides|
|Alan Cassels, University of Victoria||Audio||Slides|
|11:00 am -- Session I: Will aging bankrupt the health care system?|
|Michael Wolfson, University of Ottawa||Audio||Slides|
|Stephen Duckett, University of Alberta||Audio||Slides|
|12:00 pm -- Lunch Presentation||Audio||Slides|
|1:15 pm -- Session II: Is it possible (or sensible) to differentiate health and social care?|
|John Sloan, University of British Columbia||Audio||Slides|
|Jon Glasby, University of Birmingham||Audio||Slides|
|Vasanthi Srinivasan, Ontario Health Systems Strategy Division||Audio||Slides|
|2:45 pm -- Session III: Aging in (what) place?|
|Carole Estabrooks, Canada Research Chair in Knowledge Translation||Audio||Slides|
|Tine Rostgaard, Danish National Institute of Social Research||Audio||Slides|
|Neena Chappell, Department of Sociology at the University of Victoria||Audio||Slides|
Day 2: February 23, 2011
|8:30 am -- Session IV: Whose death is it anyway?|
|Hsien Seow, Cancer Care Ontario Research Chair||Audio||Slides|
|Dr. Michael Dolan, Internal Medicine Physician||Audio||Slides|
|Hon. Sharon Carstairs, P.C., Liberal Senate Forum||Audio|
|10:30 am -- Session V: Is aging a disease?|
|Matthew Farrer, Centre for Molecular Medicine and Therapeutics||Audio||Slides|
|Ross Upshur, University of Toronto Joint Centre for Bioethics||Audio||Slides|
|12:00 pm -- Closing Plenary Speaker|
|Steven Lewis, Health Care Consultant, Saskatoon||Audio|